AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20728932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hepatitis B vaccine)
Number of subjects: 56302
Study 18279190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemospan (200 to 1000 mL)
Number of subjects: 30
Study 18279190 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (control group)
Number of subjects: 30
Study 15834928 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+D (neoadjuvant chemotherapy with docetaxel)
Number of subjects: 121
Study 15834928 — intervention group
Group type: COMPARATOR
Intervention: AC (neoadjuvant chemotherapy without docetaxel)
Number of subjects: 121
Study 14501008 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin treatment
Number of subjects: 0
Study 14501008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10507279 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 10507279 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 7795834 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 7795834 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of dietary sodium
Number of subjects: 0
Study 7795834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of weight loss and reduction of dietary sodium
Number of subjects: 0
Study 1940817 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder intervention
Number of subjects: 1068
Study 1940817 — intervention group
Group type: COMPARATOR
Intervention: No postcard reminder (Control)
Number of subjects: 1068
Study 1940817 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder intervention (aged 65 and over)
Number of subjects: 1068
Study 1940817 — intervention group
Group type: COMPARATOR
Intervention: No postcard reminder (Control, aged 65 and over)
Number of subjects: 1068
Study 7457492 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 150
Study 7457492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheotomy
Number of subjects: 150
Study 31277537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihuang Decoction (DHD), taken orally, one dose each time, twice a week for one year
Number of subjects: 72
Study 31277537 — intervention group
Group type: COMPARATOR
Intervention: Alendronate sodium 70 mg orally once a week for one year
Number of subjects: 72
Study 31277537 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BMD, serum beta-CTX, and serum SOST between DHD and alendronate groups after treatment
Number of subjects: 72
Study 28378600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training plus non-invasive ventilatory support
Number of subjects: 46
Study 28378600 — intervention group
Group type: COMPARATOR
Intervention: Combined aerobic and resistance training alone
Number of subjects: 46
Study 26804967 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 2 (dual route/dual release fixed dose combination tablet)
Number of subjects: 12
Study 26804967 — intervention group
Group type: COMPARATOR
Intervention: Formulation 1 (testosterone solution for sublingual administration and sildenafil tablet)
Number of subjects: 12
Study 26804967 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 2
Number of subjects: 12
Study 26804967 — intervention group
Group type: COMPARATOR
Intervention: Formulation 1
Number of subjects: 12
Study 25005572 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-distribution door-to-door visits with educational messages and assistance in hang-up of nets.
Number of subjects: 0
Study 25005572 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two additional door-to-door visits.
Number of subjects: 0
Study 25005572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention visits).
Number of subjects: 0
Study 23477707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine plus Ginkgo Biloba extract (250mg ticlopidine plus 80mg Ginkgo Biloba extract twice daily)
Number of subjects: 127
Study 23477707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250mg twice daily)
Number of subjects: 127
Study 23477707 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75mg daily)
Number of subjects: 127
Study 23477707 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 127
Study 20864061 — intervention group
Group type: COMPARATOR
Intervention: Jaw lift maneuver (Group J)
Number of subjects: 100
Study 20864061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue traction using a padded artery forceps (Group T)
Number of subjects: 100
Study 17588604 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (one-day dose)
Number of subjects: 19
Study 17588604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15889241 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. citalopram
Number of subjects: 12
Study 14529054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 440 microg
Number of subjects: 262
Study 14529054 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 400 microg
Number of subjects: 262
Study 14529054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 10357038 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly ECT
Number of subjects: 40
Study 10357038 — intervention group
Group type: COMPARATOR
Intervention: Once weekly ECT
Number of subjects: 40
Study 10357038 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-seizure FD at first ECT
Number of subjects: 40
Study 8647503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal membranes that have ruptured 12 hours before onset of labor
Number of subjects: 0
Study 8647503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study 8348280 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8980 24 mg
Number of subjects: 60
Study 8348280 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8980 48 mg
Number of subjects: 60
Study 8348280 — intervention group
Group type: COMPARATOR
Intervention: OM-8980 6 mg
Number of subjects: 60
Study 8348280 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 60
Study 3745529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg twice a day for 5 days
Number of subjects: 157
Study 3745529 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of oral acyclovir 200 mg five times a day
Number of subjects: 157
Study 30168209 — intervention group
Group type: EXPERIMENTAL
Intervention: New X-ray system (AlluraClarity FD20/10, Philips Healthcare)
Number of subjects: 122
Study 30168209 — intervention group
Group type: COMPARATOR
Intervention: Reference X-ray modality (Allura Xper FD10, Philips Healthcare)
Number of subjects: 122
Study 26791931 — intervention group
Group type: EXPERIMENTAL
Intervention: 29 MHz micro-ultrasound system with PRI-MUS protocol
Number of subjects: 2000
Study 24463223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure sensor/metronome device (CPREzy)
Number of subjects: 3
Study 24463223 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer device (Phillips Q‐CPR)
Number of subjects: 3
Study 24463223 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple metronome
Number of subjects: 3
Study 24637998 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-node radiotherapy (IN-RT) omitted after negative early PET scan following two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1137
Study 24637998 — intervention group
Group type: COMPARATOR
Intervention: Standard combined-modality treatment (including IN-RT)
Number of subjects: 1137
Study 21806490 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter with extra‐amniotic saline infusion
Number of subjects: 188
Study 21806490 — intervention group
Group type: COMPARATOR
Intervention: Cook cervical ripening balloon
Number of subjects: 188
Study 19089532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg TID)
Number of subjects: 0
Study 19089532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17200777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 5750 anti‐Xa IU s.c. twice daily
Number of subjects: 60
Study 17200777 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet treatment
Number of subjects: 60
Study 15831779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 77
Study 11937423 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic monotherapy
Number of subjects: 4795
Study 11937423 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside-containing combination therapy
Number of subjects: 4795
Study 9701716 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (0.3 mg/kg, orally)
Number of subjects: 34
Study 8532263 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine peritoneal closure
Number of subjects: 106
Study 8532263 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal closure
Number of subjects: 106
Study 1984877 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 units/2‐5 min)
Number of subjects: 370
Study 1984877 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 million units/60 min)
Number of subjects: 370
Study 6841923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (chlorthalidone 15 mg and clonidine 0.1 mg)
Number of subjects: 30
Study 6841923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30820660 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stimulation (temperature increase from 20 to 40 °C at 2 °C/min)
Number of subjects: 14
Study 30820660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulation (temperature decrease from 40 to 20 °C at 2 °C/min)
Number of subjects: 14
Study 30820660 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stimulation (temperature increase)
Number of subjects: 14
Study 29491276 — intervention group
Group type: EXPERIMENTAL
Intervention: Passion fruit seed extract (5 mg piceatannol)
Number of subjects: 32
Study 29491276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 32
Study 27074935 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 703
Study 27074935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 24962549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical recombinant human EGF (rhEGF) cream applied twice daily for six weeks
Number of subjects: 20
Study 24962549 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control) applied twice daily for six weeks
Number of subjects: 20
Study 22424564 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS (subthalamic nucleus or globus pallidus internus)
Number of subjects: 24
Study 22424564 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS+DOPA (both medication and DBS on)
Number of subjects: 24
Study 22424564 — intervention group
Group type: COMPARATOR
Intervention: OFF/OFF (off medication with DBS switched off)
Number of subjects: 24
Study 22424564 — intervention group
Group type: COMPARATOR
Intervention: DOPA (on medication with DBS off)
Number of subjects: 24
Study 22424564 — intervention group
Group type: COMPARATOR
Intervention: GPi group
Number of subjects: 24
Study 22424564 — intervention group
Group type: COMPARATOR
Intervention: PD control group
Number of subjects: 24
Study 19175369 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 19
Study 19175369 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp70
Number of subjects: 19
Study 19175369 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 19
Study 19175369 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp30
Number of subjects: 19
Study 17460427 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravitreal triamcinolone injection (4 mg/0.1 ml)
Number of subjects: 20
Study 17460427 — intervention group
Group type: COMPARATOR
Intervention: Late intravitreal triamcinolone injection (4 mg/0.1 ml)
Number of subjects: 20
Study 15234072 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil (0.5 g/kg body weight/day)
Number of subjects: 81
Study 15234072 — intervention group
Group type: COMPARATOR
Intervention: TAG oil (0.5 g/kg body weight/day)
Number of subjects: 81
Study 15234072 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 81
Study 15234072 — intervention group
Group type: COMPARATOR
Intervention: TAG oil
Number of subjects: 81
Study 15234072 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil and TAG oil
Number of subjects: 81
Study 12399675 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 63
Study 12399675 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 0.75% gel
Number of subjects: 63
Study 12399675 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 63
Study 9661552 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. patient-controlled analgesia (PCA) with morphine
Number of subjects: 45
Study 9661552 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous 3-in-1 block
Number of subjects: 45
Study 9661552 — intervention group
Group type: EXPERIMENTAL
Intervention: epidural analgesia
Number of subjects: 45
Study 8187514 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic concentrations of faecal enzymes
Number of subjects: 0
Study 8187514 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffer (pH = 8)
Number of subjects: 0
Study 8187514 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme mixture containing lipase
Number of subjects: 0
Study 8187514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged occlusive exposure to digestive enzymes
Number of subjects: 0
Study 1792811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 mg bid or 5 mg)
Number of subjects: 67
Study 1792811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 6576203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose methotrexate (ID-MTX) pulses
Number of subjects: 145
Study 6576203 — intervention group
Group type: COMPARATOR
Intervention: Conventional vincristine (VCR) pulses
Number of subjects: 145
Study 6576203 — intervention group
Group type: EXPERIMENTAL
Intervention: COALL-80 induction therapy modification
Number of subjects: 145
Study 30811354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive as an adjunct to standard three-layer closure
Number of subjects: 29
Study 30811354 — intervention group
Group type: COMPARATOR
Intervention: Standard three-layer closure with staples (Control)
Number of subjects: 29
Study 30811354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive and standard closure
Number of subjects: 29
Study 29772277 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1%‐fluorometholone (FML), 4 drops daily for 22 days
Number of subjects: 41
Study 29772277 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl‐alcohol (PA), 4 drops daily for 22 days
Number of subjects: 41
Study 26874371 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNu Multiplus(®) in study CLCs
Number of subjects: 20
Study 26874371 — intervention group
Group type: EXPERIMENTAL
Intervention: SoloCare Aqua™ in study CLCs
Number of subjects: 20
Study 26874371 — intervention group
Group type: COMPARATOR
Intervention: New lenses in new cases with fresh solution (control CLCs)
Number of subjects: 20
Study 24313663 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief functional relaxation (FR) training via MP3 player
Number of subjects: 48
Study 24313663 — intervention group
Group type: COMPARATOR
Intervention: Standard care (15 minutes of sitting quietly)
Number of subjects: 48
Study 21635200 — intervention group
Group type: EXPERIMENTAL
Intervention: Early epidural analgesia (EEA)
Number of subjects: 41
Study 21635200 — intervention group
Group type: COMPARATOR
Intervention: Conventional epidural analgesia (CEA)
Number of subjects: 41
Study 19279518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg/day)
Number of subjects: 40
Study 19279518 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide (3.0 g/day)
Number of subjects: 40
Study 17704416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapuleucel-T (APC8024) infusion at weeks 0, 2, and 4; no specific dosage mentioned.
Number of subjects: 19
Study 15058177 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 133
Study 15058177 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer/composite open sandwich restorations
Number of subjects: 133
Study 15058177 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 133
Study 12238277 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antibiotherapy for 10 to 14 days with a double dose of an anti-secretory drug
Number of subjects: 0
Study 12238277 — intervention group
Group type: COMPARATOR
Intervention: Current regimen (7 days of double-dose anti-secretory drug and 2 antibiotics, followed by usual dose for 3 weeks)
Number of subjects: 0
Study 9525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg twice daily
Number of subjects: 24
Study 9525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 240 mg/day
Number of subjects: 24
Study 9525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg single dose
Number of subjects: 24
Study 9525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 240 mg single dose
Number of subjects: 24
Study 9525444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9525444 — intervention group
Group type: COMPARATOR
Intervention: Clemastine 2 mg twice daily
Number of subjects: 24
Study 7848623 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug therapy (one of five active drugs)
Number of subjects: 423
Study 7848623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional‐hygienic therapy and active drugs
Number of subjects: 423
Study 7848623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 2595644 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous PK 11195
Number of subjects: 16
Study 2595644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 4590668 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol at a dosage of 400 to 800 mug/day for three months
Number of subjects: 120
Study 4590668 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate) at a daily maintenance dose of 200 mug/day
Number of subjects: 120
Study 4590668 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate)
Number of subjects: 120
Study 31491556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (BL) exposure (>8000 lx) during memory encoding
Number of subjects: 0
Study 31491556 — intervention group
Group type: COMPARATOR
Intervention: Control light (CL) exposure (<500 lx) during memory encoding
Number of subjects: 0
Study 31491556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (BL) exposure
Number of subjects: 0
Study 31491556 — intervention group
Group type: COMPARATOR
Intervention: Control light (CL) exposure
Number of subjects: 0
Study 28513492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 46
Study 28513492 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbscan
Number of subjects: 46
Study 28513492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirius
Number of subjects: 46
Study 25683592 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg daily)
Number of subjects: 256
Study 25683592 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (0.5 mg kg(-1) daily)
Number of subjects: 256
Study 25683592 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 256
Study 25683592 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 256
Study 23533302 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) 1.2 g/day for 12 weeks
Number of subjects: 0
Study 22134936 — intervention group
Group type: EXPERIMENTAL
Intervention: sedated endoscopy (sEGD)
Number of subjects: 60
Study 22134936 — intervention group
Group type: EXPERIMENTAL
Intervention: unsedated transnasal endoscopy (uTNE)
Number of subjects: 60
Study 22134936 — intervention group
Group type: EXPERIMENTAL
Intervention: video capsule endoscopy (VCE)
Number of subjects: 60
Study 19620697 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric compression applied by a crossed-tape technique (group A)
Number of subjects: 200
Study 19620697 — intervention group
Group type: COMPARATOR
Intervention: No eccentric compression (group B)
Number of subjects: 200
Study 16798758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp ATP therapy
Number of subjects: 176
Study 16798758 — intervention group
Group type: COMPARATOR
Intervention: Burst+ ATP therapy
Number of subjects: 176
Study 16798758 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 176
Study 12769158 — intervention group
Group type: EXPERIMENTAL
Intervention: HDk lotrafilcon A soft contact lens
Number of subjects: 134
Study 12769158 — intervention group
Group type: COMPARATOR
Intervention: LDk etafilcon A soft contact lens
Number of subjects: 134
Study 12769158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lenses
Number of subjects: 134
Study 11261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurses providing information, advice and support to caregivers and patients at home during the first year after a stroke.
Number of subjects: 45
Study 11261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methods using semi-structured interviews.
Number of subjects: 45
Study 11261130 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 45
Study 9048271 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release oral azathioprine 200 mg
Number of subjects: 30
Study 9048271 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release oral azathioprine 400 mg
Number of subjects: 30
Study 9048271 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release oral azathioprine 600 mg
Number of subjects: 30